VEGFA and hepatocellular carcinoma: To be specific, it can inhibit the tyrosine kinase of the VEGF signaling pathway, thereby reducing tumor angiogenesis and RAF kinase, resulting in a decrease in cell proliferation.[31] Therefore, the combination of TACE plus sorafenib reduces angiogenesis.[32,33] Secondly, TACE and sorafenib may affect the prognosis of HCC through various complex abnormal regulation of miRNA.[34] Thirdly, sorafenib may ameliorate lipiodol retention in HCC,[35] which offers support for better local control of advanced HCC.